Real Life Evaluation of Lupron in the Management of Prostate Cancer: A Canadian Post Marketing Observational Study
Status
Conditions
Details and patient eligibility
About
The purpose of this study is to evaluate the Canadian Real Life Evaluation of the Effectiveness of Lupron in the Management of Prostate Cancer.
Full description
This is a Canadian Post Marketing Observational Study utilizing a prospective cohort design. Patients with Prostate Cancer who are prescribed Lupron will be entered into the study cohort and will be followed for a maximum of 36 months with recommended assessments at 3, 6, 12, 18, 24, 30 and 36 months after baseline. Treatment of the patients and follow up will be according to the physician's judgment, regional regulations and the product monograph.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
- Has provided written informed consent allowing the use of their data for the study and providing permission for contact by the study personnel
- Diagnosed with Prostate Cancer
- Prescribed Lupron as part of his treatment by his treating physician
Exclusion criteria
- Currently participating in another prospective study including controlled clinical trials and observational studies.
- Patient cannot or will not sign informed consent
- Survival expectancy less than 2-3 years as per the treating physician's judgment
- Presence of other condition that, in the opinion of the treating physician, prohibits the patient from participating in the study or obscures the assessment of the treatment of Prostate Cancer
- History of alcohol or drug abuse
- No longer than 6 months of therapy if currently on luteinizing hormone-releasing hormone (LHRH) treatment
Trial design
552 participants in 1 patient group
Trial contacts and locations
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal